Lactate is the end product of anaerobic glycolysis. In situations of hypoperfusion or hypoxia, pyruvate will no longer enter into mitochondria for aerobic metabolism, but instead, it is preferentially reduced to lactate, resulting in accumulation of lactate in the blood. The process is an adaptive mechanism to produce energy in situations of low oxygen supply, but at the expense of deteriorating acidosis. [1, 2] Lactate is produced in the majority of tissues in human being, but the greatest producers include red blood cells, intestine, brain, and muscles. In critically ill patients, the daily production of lactate is approximately 1300 mmol per day and the concentrations of arterial lactate represents the balance between production of clearance. Lactic acidosis or hyperlactatemia occurs when production exceeds clearance, which has been confirmed to be associated with worse clinical outcomes in critically ill patients. Even a mild increase in arterial lactate is associated with higher risk for worse outcome.
Such association has been replicated in several patient populations, including trauma, cardiac arrest, severe sepsis and septic shock. [3] [4] [5] [6] Single measurement of lactate cannot improve clinical outcome, but therapeutic strategies that can potentially decrease arterial lactate may be associated with improved clinical outcomes. The aim of such strategy is to reverse the global tissue hypoxia. The idea of lactate clearance (LC) is to accommodate this concept. Many clinical studies have demonstrated that patients who clear elevated lactate have better clinical outcomes as compared to the non-clearer; furthermore, patients with faster lactate clearance are more likely to survive than slower ones. [7] [8] [9] [10] [11] However, the F o r p e e r r e v i e w o n l y accurate predictive value of lactate clearance in predicting mortality has not been well defined and conflicting results exist among studies. We here presented a study protocol for a systematic review to investigate the association of lactate clearance with clinical outcomes.
Methods

Inclusion criteria of studies Participants
Critically ill adult patients will be included in our analysis. This population will include heterogeneous study participants, including patients with sepsis or severe sepsis, trauma, surgical ICU patients, and so on. Children will be excluded because lactate metabolism in children is different. [12] Exposed group and control group Patients with lactate clearance are used as the exposed group. Lactate clearance will be defined from two aspects: magnitude and time needed for the clearance. A threshold of 10% reduction from baseline or normalization is employed; and 24-hour is used as the time frame for lactate clearance. The control group is defined as those without lactate clearance.
Studies to be included
Both observational cohort studies and randomized controlled trials (RCT) will be included for analysis. For lactate clearance to be predictive of clinical outcome, it should be independent of the intervention applied in RCTs. We will search four databases including EBSCO, Pubmed, Scopus and ISI Web of knowledge from inception to Feb. 2014. There will be no language restrictions in the electronic search for studies.
The searched item will include terms related to critically ill patients (intensive care, ICU, critically ill, intensive care unit, critical care, severely ill and emergency) and terms related to lactate clearance (lactate clearance, lactate normalization, kinetics and lactic clearance). The specific searching strategies for the four databases are shown in table 1 . References of all relevant articles will be searched by hand to uncover other potentially eligible studies. If necessary, experts of this field will be contacted for additional studies for our topic.
Data collection
A standardized form will be made for data abstraction. The following data will be extracted from original articles: the name of the first author, publication year, male percentage, subjects (ie, sepsis, major surgery) and setting (ie, medical ICU, surgical ICU, or emergency department), mean age of study population, sample size, mortality, definition of clearance (ie, the percentage reduction and time frame for lactate clearance), and the initial lactate level. Data used for meta-analysis will be as follows:
the numbers of survivors and non-survivors in LC group and non-LC groups; area under receiver operating characteristics curve (AU-ROC) and corresponding F o r p e e r r e v i e w o n l y confidence interval; cutoff value of LC for the best sensitivity and specificity to predict mortality. Other secondary outcomes will be included if available in original articles. If these data were unavailable in original articles, we tried to contact the corresponding authors for more data.
Quality assessment of included studies Newcastle Ottawa Scale for cohort study will be employed to assess reporting quality of included original studies. [13] This scale comprises eight items evaluating the quality of observational cohort studies in terms of selection, comparability and outcome. If patients were not followed up for the entire length of stay in hospital (e.g. ICU mortality), the follow-up was thought to be not long enough for the outcome to occur. Table 2 shows the criteria used for quality assessment adapted from Newcastle Ottawa Scale.
Data synthesis
Mantel-Haenszel methods will be used to combine effect size for fixed-effect model.
Otherwise, if there are significant heterogeneity in component studies, random-effects method will be used by assuming that the different studies are estimating different effects. This method is based on inverse variance approach, assigning study weights according to variance. [14] We will report relative risk (RR) of death for those with lactate clearance and those without, with a RR<1 indicating LC is associated with lower risk of death and a RR>1 indicating LC is a risk factor for death. For continuous outcome variables, the mean difference will be used to measure effect size.
Standard deviations together with sample size will be used to assign weight to each study. For variables in difference scale, standardized mean difference will be used, which standardizes the mean difference by standard deviation to a single scale.
The diagnostic performance of LC in predicting mortality will be of interest to clinicians, thus we will synthesize data regarding diagnostic statistics. Due to expected substantial between-study heterogeneity, we will employ hierarchical summary receiver operating characteristic (HSROC) model. This model assumes that there is an underlying ROC curve in each study with parameters α and β that represent the accuracy and asymmetry of the ROC curve. [15] The reported pooled statistics include sensitivity, specificity, positive likelihood ratio and negative likelihood ratio. Data synthesis will be performed by using the software Stata (College Station, Texas 77845 USA).
Heterogeneity
Heterogeneity will be assessed by using a statistical test. Inconsistency across component studies will be quantified by using the equation:
where Q is the chi-squared statistic and df is its degree of freedom. [16] 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The result showed that quantitative resuscitation based on lactate clearance was non-inferior to that based on central venous oxygenation saturation. [20] The other showed that resuscitation strategy based on both lactate clearance and central venous oxygenation saturation was associated with a 9.6% absolute reduction in mortality. [21] The results of these two RCTs are encouraging and inspire more researches on this field. Many studies have been carried out aiming to investigate the association of lactate clearance and mortality. However, given the conflicting results obtained from these studies, it is still unclear whether lactate clearance is an useful biomarker for the prediction of death. Therefore, a systematic review is mandatory at this stage to clarify this linkage. Subgroup analysis restricting to patients with sepsis will provide further insights into the clinical usefulness of lactate clearance. analysis and interpretation of data; X.X helped i drafting the article and revising it critically for important intellectual content; and all authors final approval of the version to be published.
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#1 AND #2 S1 AND S2 #1 AND #2 #1 AND #2 Table 2 The Newcastle-Ottawa scale (NOS) for assessing the quality of included studies Selection Representativeness of the exposed cohort This item will be assigned a "☆" when all eligible patients with LC are included in analysis during study period.
Selection of the non-exposed cohort
This item will be assigned a "☆" when all eligible patients with non-LC are included in analysis during study period.
Ascertainment of exposure This item will be assigned a "☆" when lactate is directly obtained from medical chart, not by reporting from the patient.
Outcome of interest is not present at the start of study This item will be assigned a " ☆ " when death is not occurred within the time frame for determining LC.
Comparability Comparability of cohorts on the basis of design or analysis
Baseline characteristics of LC and non-LC patients are comparable. Usually this can be found in table 1.
Outcome Assessment of outcome This item will be assigned a " ☆ " when mortality is assessed by investigator, not by the report of the patient's family or next-of-kin.
Is follow-up long enough for outcome to occur
The adequate follow-up is during hospital stay.
Adequacy of follow up of cohort
This item will be assigned a " ☆ " when follow up rate>95%.
Abbreviation: LC, lactate clearance. 
Methods and analysis:
Critically ill adult patients will be included in our analysis.
This population will include heterogeneous study participants, including patients with sepsis or severe sepsis, trauma, surgical ICU patients, and so on. We will search four databases including EBSCO, Pubmed, Scopus and ISI Web of knowledge from inception to Feb. 2014. There will be no language restrictions in the electronic search for studies. Newcastle Ottawa Scale for cohort study will be employed to assess reporting quality of included original studies. We will report pooled relative risk (RR) of death for those with lactate clearance and those without. Diagnostic performance of lactate clearance in predicting mortality will be explored by using hierarchical summary receiver operating characteristic (HSROC) model.
Ethics and dissemination:
The protocol for the systematic review has been registered in PROSPERO (registration number: CRD42013006511). The study will be disseminated electronically and in print. It will also be presented to conferences related to critical care medicine. hypoxia, pyruvate will no longer enter into mitochondria for aerobic metabolism, but instead, it is preferentially reduced to lactate, resulting in accumulation of lactate in the blood. The process is an adaptive mechanism to produce energy in situations of low oxygen supply, but at the expense of deteriorating acidosis. [1, 2] Lactate is produced in the majority of tissues in human being, but the main producers include red blood cells, intestine, brain, and muscles. In critically ill patients, the daily production of lactate is approximately 1300 mmol per day and the concentrations of arterial lactate represents the balance between production and clearance. Lactic acidosis or hyperlactatemia occurs when production exceeds clearance, which has been confirmed to be associated with worse clinical outcomes in critically ill patients.
Even a mild increase in arterial lactate is associated with higher risk for worse outcome. Such association has been replicated in several patient populations, including trauma, cardiac arrest, severe sepsis and septic shock. [3] [4] [5] [6] We here presented a study protocol for a systematic review to investigate the association of lactate clearance with clinical outcomes.
Methods
Inclusion criteria of studies
Participants
Study endpoints
The primary outcome is mortality. The pooled data will show how the risk of death differs between patients with and without LC. Furthermore, the diagnostic performance of LC in predicting mortality will be reported. Statistics for diagnostic performance including sensitivity, specificity, positive likelihood ratio and negative likelihood ratio will be reported.
Studies to be included
Both observational cohort studies and randomized controlled trials (RCT) will be included for analysis. Observational studies will include both prospective and retrospective studies.
Search methods for identifying studies
We will search four databases including EBSCO, Pubmed, Scopus and ISI Web of knowledge from inception to Feb. 2014. There will be no language restrictions in the electronic search for studies.
The searched item will include terms related to critically ill patients (intensive care, ICU, critically ill, intensive care unit, critical care, severely ill and emergency) and terms related to lactate clearance (lactate clearance, lactate normalization, kinetics and lactic clearance). The specific searching strategies for the four databases are shown in table 1. References of all relevant articles will be searched by hand to uncover other potentially eligible studies. If necessary, experts of this field will be contacted for additional studies for our topic. A standardized form will be made for data abstraction. The following data will be extracted from original articles: the name of the first author, publication year, male percentage, subjects (ie, sepsis, major surgery) and setting (ie, medical ICU, surgical ICU, or emergency department), mean age of study population, sample size, mortality, definition of clearance (ie, the percentage reduction and time frame for lactate clearance), and the initial lactate level. Data used for meta-analysis will be as follows:
Data collection
the numbers of survivors and non-survivors in LC group and non-LC groups; area under receiver operating characteristics curve (AU-ROC) and corresponding confidence interval; cutoff value of LC for the best sensitivity and specificity to predict mortality. Other secondary outcomes will be included if available in original articles. If these data were unavailable in original articles, we tried to contact the corresponding authors for more data.
Quality assessment of included studies Newcastle Ottawa Scale for cohort study will be employed to assess reporting quality of included original studies. [13] This scale comprises eight items evaluating the quality of observational cohort studies in terms of selection, comparability and outcome. If patients were not followed up for the entire length of stay in hospital (e.g.
ICU mortality), the follow-up was thought to be not long enough for the outcome to occur. Table 2 shows the criteria used for quality assessment adapted from Newcastle
Ottawa Scale. 
Data synthesis
The diagnostic performance of LC in predicting mortality will be of interest to clinicians, thus we will synthesize data regarding diagnostic statistics. Due to expected substantial between-study heterogeneity, we will employ hierarchical summary receiver operating characteristic (HSROC) model. This model assumes that there is an underlying ROC curve in each study with parameters α and β that represent the accuracy and asymmetry of the ROC curve. [15] The reported pooled statistics include sensitivity, specificity, positive likelihood ratio and negative likelihood ratio.
Data synthesis will be performed by using the software Stata (College Station, Texas 77845 USA). indicating moderate heterogeneity, 60%-90% indicating substantial heterogeneity, and >90% indicating considerable heterogeneity. Heterogeneity will be explored by using subgroup analysis restricting to sepsis or septic shock. Depending on the number of studies available, other subgroup analyses involving trauma, major operation will be explored. Sensitivity analysis will be performed by excluding retrospective studies.
Publication bias
Contour enhanced funnel plot will be used to detect publication bias. Relative risk from each study is plotted against their variance. Asymmetrical appearance of the plot indicates the presence of publication bias. Contours of statistical significance are overlaid on the funnel plot, which facilitates the assessment of whether the areas where component studies locate are areas of statistical significance and whether the areas where studies are potentially missing are areas of low significance. In situations when studies are missing in areas of low significance, it is possible that the asymmetry is due to publication bias. Otherwise, if the areas where studies are The result showed that quantitative resuscitation based on lactate clearance was non-inferior to that based on central venous oxygenation saturation. [20] The other showed that resuscitation strategy based on both lactate clearance and central venous oxygenation saturation was associated with a 9.6% absolute reduction in mortality. [21] The results of these two RCTs are encouraging and inspire more researches on this field. Many studies have been carried out aiming to investigate the association of lactate clearance and mortality. [7] [8] [9] [10] [11] These studies reported conflicting results. For instance, the sensitivity of lactate clearance in predicting mortality ranged from 0.45 to 0.97; and the specificity ranged from 0.52 to 0.84. Such conflicting result may confuse clinicians on whether lactate clearance can be utilized for clinical decision 
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Methods and analysis:
Ethics and dissemination:
The protocol for the systematic review has been registered in PROSPERO (registration number: CRD42013006511). The study will be disseminated electronically and in print. It will also be presented to conferences related to critical care medicine. hypoxia, pyruvate will no longer enter into mitochondria for aerobic metabolism, but instead, it is preferentially reduced to lactate, resulting in accumulation of lactate in the blood. The process is an adaptive mechanism to produce energy in situations of low oxygen supply, but at the expense of deteriorating acidosis. [1, 2] Lactate is produced in the majority of tissues in human being, but the greatest main producers include red blood cells, intestine, brain, and muscles. In critically ill patients, the daily production of lactate is approximately 1300 mmol per day and the concentrations of arterial lactate represents the balance between production of and clearance. Lactic acidosis or hyperlactatemia occurs when production exceeds clearance, which has been confirmed to be associated with worse clinical outcomes in critically ill patients.
Even a mild increase in arterial lactate is associated with higher risk for worse outcome. Such association has been replicated in several patient populations, including trauma, cardiac arrest, severe sepsis and septic shock. [3] [4] [5] [6] Single measurement of lactate cannot improve clinical outcome, but therapeutic strategies that can potentially decrease arterial lactate may be associated with likely to survive than slower onesthose with slow LC. [7] [8] [9] [10] [11] However, the accurate predictive valuediagnostic performance of lactate clearance in predicting mortality has not been well defined and conflicting results exist among studies. For instance, the area under receiver operating characteristic curve (ROC) ranged from 0.67 to 0.87 as reported by different studies. We here presented a study protocol for a systematic review to investigate the association of lactate clearance with clinical outcomes.
Methods
Participants
Study endpoints
Studies to be included
Both observational cohort studies and randomized controlled trials (RCT) will be included for analysis. For lactate clearance to be predictive of clinical outcome, it should be independent of the intervention applied in RCTs. Observational studies will include both prospective and retrospective studies.
Search methods for identifying studies
The searched item will include terms related to critically ill patients (intensive care, ICU, critically ill, intensive care unit, critical care, severely ill and emergency) and terms related to lactate clearance (lactate clearance, lactate normalization, kinetics and lactic clearance). The specific searching strategies for the four databases are shown in 
Data collection
Quality assessment of included studies
Newcastle Ottawa Scale for cohort study will be employed to assess reporting quality of included original studies. [13] This scale comprises eight items evaluating the quality of observational cohort studies in terms of selection, comparability and outcome. If patients were not followed up for the entire length of stay in hospital (e.g.
ICU mortality), the follow-up was thought to be not long enough for the outcome to occur. Table 2 shows the criteria used for quality assessment adapted from Newcastle Ottawa Scale.
Data synthesis
The diagnostic performance of LC in predicting mortality will be of interest to clinicians, thus we will synthesize data regarding diagnostic statistics. Due to expected substantial between-study heterogeneity, we will employ hierarchical summary receiver operating characteristic (HSROC) model. This model assumes that there is an underlying ROC curve in each study with parameters α and β that represent the accuracy and asymmetry of the ROC curve. [15] The reported pooled statistics include sensitivity, specificity, positive likelihood ratio and negative likelihood ratio. The result showed that quantitative resuscitation based on lactate clearance was non-inferior to that based on central venous oxygenation saturation. [20] The other showed that resuscitation strategy based on both lactate clearance and central venous oxygenation saturation was associated with a 9.6% absolute reduction in mortality. [21] The results of these two RCTs are encouraging and inspire more researches on this field. Many studies have been carried out aiming to investigate the association of lactate clearance and mortality. [7] [8] [9] [10] [11] These studies reported conflicting results. For 
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The study did not involve human subject and informed consent was waived. Table 2 The Newcastle-Ottawa scale (NOS) for assessing the quality of included studies Selection Representativeness of the exposed cohort This item will be assigned a "☆" when all eligible patients with LC are included in analysis during study period.
Selection of the non-exposed cohort This item will be assigned a "☆" when all eligible patients with non-LC are included in analysis during study period.
Outcome of interest is not present at the start of study This item will be assigned a " ☆ " when death is not occurred within the time frame for determining LC. Is follow-up long enough for outcome to occur
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